Table 3 Multivariate Analysis of Prognostic Factors Associated with Clinical Outcomes.

From: The Cumulative Cisplatin Dose Affects the Long-Term Survival Outcomes of Patients with Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy

Endpoint

Variable

P a

HR

95% CI for HR

DFS

N classification

0.016

1.717

1.105–2.667

 

Cumulative dose

0.048

0.515

0.267–0.995

 

EBV DNA

<0.001

3.659

2.315–5.783

OS

N classification

0.033

1.851

1.051–3.260

 

Age

0.026

1.843

1.076–3.158

 

EBV DNA

<0.001

3.298

1.800–6.041

LRRFS

EBV DNA

0.013

2.228

1.183–4.196

DMFS

EBV DNA

<0.001

4.725

2.585–8.638

  1. Abbreviations: DFS = disease-free survival; OS = overall survival; LRRFS = locoregional relapse-free survival; DMFS = distant metastases-free survival; HR = hazard ratio; CI = confidence interval.
  2. aMultivariate P-values were calculated using an adjusted Cox proportional-hazards model. The following parameters were included in the Cox proportional hazards model with backward elimination: gender (male vs. female), age (≥50 y vs. <50 y), pathological type (type I vs. type II/III), smoking (yes vs. no), drinking (yes vs. no), EBV DNA (≥1460 copies/ml vs. <1460 copies/ml), LDH (≥245 U/L vs. <245 U/L), cisplatin regimen (weekly vs. 3-week), T category (T1–2 vs. T3–4), N category (N0–1 vs. N2–3), cumulative cisplatin dose (≥240 mg/m2 vs. <240 mg/m2).
Back to article page